Project Grant R01DK137764

Award Date 4/15/24
Completion Date 2/29/28
Dollars Obligated $1.8M
Federal Grant Program
93.847
Assistance Type
Project Grant
Place of Performance
Durham, NC 27710, USA
Similar Awards
The U.S. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a Project Grant (CFDA 93.847 - Diabetes, Digestive, and Kidney Diseases Extramural Research) to the Icahn School of Medicine at Mount Sinai totaling $707,389.00 on August 15, 2024. The grant supports a 5-year study titled "Targeting Nonalcoholic Fatty Liver Disease During the Reproductive Period to Improve Women's Health Outcomes". The study aims to: 1) Determine the association between...
This $806,452 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) supports research investigating the mechanisms that combine type 2 diabetes and non-alcoholic fatty liver disease (NAFLD). The research aims to determine how hepatic insulin resistance can lead to the progression of NAFLD to the more severe non-alcoholic steatohepatitis (NASH), and how this...
This $478,503 Project Grant award from the National Institute of Environmental Health Sciences (NIEHS) under the Environmental Health program (CFDA 93.113) supports research to investigate the impact of prenatal exposure to per- and polyfluoroalkyl substances (PFAS) on the development of non-alcoholic fatty liver disease (NAFLD) in children. The award will leverage the existing GUSTO mother-child cohort in Singapore to conduct comprehensive assessments, including proton magnetic resonance...
This federal Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), will support research to investigate the role of lipid droplet proteins in regulating polyunsaturated fatty acid metabolism and liver inflammation in non-alcoholic fatty liver disease (NAFLD). The $272,133 award to The Trustees of the University of Pennsylvania will fund a 2-year study...
This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides $146,570 to The Trustees of the University of Pennsylvania to conduct research on functional identification of non-coding genetic variants associated with metabolic dysfunction-associated steatotic liver disease (MASLD). The key objectives of this 5-year research project are to: 1)...
The federal Project Grant award R01DK140159, funded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), aims to investigate the potential of a novel adipokine in resolving non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) in animal models. The $469,235 award, with a start date of September 1, 2024, and an ultimate completion date of June 30,...
This three-year, $3.13 million project grant from the National Institutes of Health's National Institute of Environmental Health Sciences will fund research at Michigan State University investigating the progression of non-alcoholic fatty liver disease. Specifically, the grant will test the hypothesis that activation of the aryl hydrocarbon receptor by environmental contaminants reprograms fatty acid metabolism, causing the accumulation of toxic lipid intermediates that contribute to...
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $172,060 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH). The project aims to understand the mechanism by which the Unfolded Protein Response (UPR) is dysregulated in the pathogenesis of Non-Alcoholic Steatohepatitis (NASH), a leading cause of liver...
This $243,590 Project Grant awarded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), supports research at the University of Chicago to investigate the role of the protein BNIP3 in regulating lipid metabolism and fat accumulation in the liver. The research aims to elucidate the mechanisms by which BNIP3 promotes mitophagy (selective degradation of mitochondria) and...
This federal Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides $1,558,188 to The Trustees of the University of Pennsylvania to investigate how changes in transcription factor and heterochromatin states impact liver development, homeostasis, and regeneration. The research aims to elucidate the molecular interactions between transcription...

GENOMIC IMPRINTING IN THE DEVELOPMENT OF NAFLD - ABSTRACT - GENOMIC IMPRINTING IN THE DEVELOPMENT OF NAFLD BY 2030, NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) IS PROJECTED TO AFFECT MORE THAN 100 MILLION AMERICANS, INCLUDING 10 MILLION CHILDREN. NAFLD RESULTS FROM OVERACCUMULATION OF FAT IN THE LIVER AND CAN PROGRESS TO NON-ALCOHOLIC STEATOHEPATITIS AND CIRRHOSIS, LEADING TO SIGNIFICANT MORBIDITY AND MORTALITY EVEN AMONG CHILDREN AND ADOLESCENTS. ACCUMULATING EVIDENCE INDICATES THAT EARLY LIFE EXPOSURES ALTER GENE EXPRESSION AND INFLUENCE THE RISK FOR NAFLD, BUT REGIONS OF THE GENOME TARGETED BY THESE EXPOSURES REMAIN UNCLEAR. WE HYPOTHESIZE THAT ABERRANT METHYLATION AT IMPRINT CONTROL REGIONS (ICRS), DISCRETE LOCI WHICH REGULATE EXPRESSION OF SPECIFIC GENES AND THE FUNCTION OF GENE NETWORKS, CONTRIBUTES SUBSTANTIALLY TO NAFLD. MEASURING THE IMPACT OF EPIGENETIC MODIFICATIONS THAT ALTER NAFLD RISK HAS BEEN CHALLENGING DUE TO THE LACK OF TOOLS FOR COMPREHENSIVE MEASUREMENT OF EPIGENETIC MODIFICATIONS, LONGITUDINAL DATA, COHORT DIVERSITY, ACCURATE NON-INVASIVE MARKERS OF LIVER FAT AND FIBROSIS, AS WELL AS THE TEMPORAL AMBIGUITY BETWEEN EXPOSURE AND OUTCOMES. TO OVERCOME THESE OBSTACLES, WE HAVE COMPREHENSIVELY IDENTIFIED DNA METHYLATION-CONTROLLED REGULATORY REGIONS FOR GENOMICALLY IMPRINTED GENES, MANY OF WHICH ARE IMPLICATED IN METABOLIC DISEASE, GROWTH AND DEVELOPMENT. ONCE ESTABLISHED IN THE GAMETES, THESE ICRS ARE STABLY TRANSMITTED DURING MITOTIC CELL DIVISION AND ARE THUS VERY SIMILAR ACROSS TISSUES. IMPORTANTLY, IMPRINTED GENES PLAY KEY ROLES IN GROWTH AND METABOLISM, UNDERSCORING PLAUSIBILITY IN THE ETIOLOGY OF NAFLD. THE OVERARCHING GOAL IS TO UTILIZE THESE NOVEL ICRS TO IDENTIFY METHYLATION CHANGES ASSOCIATED WITH NAFLD DEVELOPMENT. WE WILL LEVERAGE THE RESOURCES OF OUR MULTI- ETHNIC, PRE-BIRTH, LONGITUDINAL COHORT, THE NEWBORN EPIGENETICS STUDY (NEST) TO EVALUATE THE OLDEST 500 CHILDREN (17-21 YEARS). WE WILL IDENTIFY ICRS AT BIRTH ASSOCIATED WITH INCREASED LIVER FAT, NAFLD, AND LIVER FIBROSIS USING MAGNETIC RESONANCE IMAGING AS WELL AS INTERMEDIATE MARKERS OF NAFLD AND METABOLIC DYSFUNCTION. ICR METHYLATION WILL BE EXAMINED IN RELATION TO METABOLIC OUTCOMES, SEX, ETHNICITY AND EARLY LIFE EXPOSURES. A 1-YEAR FOLLOW-UP OF 200 ADOLESCENTS WILL DETERMINE STABILITY OF THE ASSOCIATIONS. FINALLY, WE WILL VALIDATE THE ICR STATUS OF NAFLD-ASSOCIATED GENES IN DIFFERENT TISSUE TYPES TO DETERMINE THEIR ABILITY TO SERVE AS EARLY MARKERS OF DISEASE RISK. THIS PROPOSAL WILL CONTRIBUTE SIGNIFICANTLY TO KNOWLEDGE ON THE RELATIONSHIP BETWEEN GENOMIC IMPRINTING AND NAFLD AND CLARIFY RISK- MEDIATING REGIONS AND EXPOSURES THAT CAN BE USED TO DEVELOP EARLY DETECTION AND THERAPEUTIC TOOLS TO COMBAT THE NAFLD EPIDEMIC.

Posted 4/9/24, 12:00 AM